Floatz logo

Visilizumab

Small Intestine Cancer

Stanford Universitymonoclonal_antibodyPhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Small Intestine Cancer cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
Cancer Research UK
Phase 2BB
VINCRISTINE SULFATE
Cancer Research UK
Phase 2BB
FILGRASTIM
Cancer Research UK
Phase 2BB
Carboplatin
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Visilizumab is also rated in:

leukemiaDormant
B
Indicative ·
60 / 100
View asset →
ImmunotherapyDormant
CCC
Indicative ·
54 / 100
View asset →
graft versus host diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →